Cytokine Signalling Forum

Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated. In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.

Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.

Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy. In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre and Doctor Frank Behrens, Medical director at Goethe-University, as they discuss two interesting areas of the modern PsA therapeutic landscape. The first of the publications discussed pertains to the use of secukinumab in oligoarticular PsA. We will then go on to expand upon the latest in the evolving story begun by ORAL Surveillance, as we discuss the latest meta-analysis of the relationship between JAK inhibition and malignancies.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Laura Coates a NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing her recent paper 'Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study'.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.

Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.

Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.

Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients. In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate. In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.

Join Professor Xavier Mariette as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2023 today (Wednesday 31 May). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Professor Peter Nash as he previews our highlights this EULAR, introducing some of the top abstracts we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.

Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.

Dr Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin where she is also Medical Director of the psoriatic arthritis program. In this edition, Dr Singla discusses ehr latest paper 'Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.'

Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.

Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs. In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs. In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi. To access detailed summary slides of the papers discussed today, visit cytokinesignalling.com.

Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.